SkinHealth Q2 Sales Miss, But EBITDA Beats; $18M Securities Settlement Booked
SKIN sits 26% above its 52-week low of $0.551 on light trading volume (0.3× avg).
Summary
SkinHealth Systems delivered a mixed Q2: revenue missed but EBITDA beat, while an $18M securities settlement was booked and a reverse split is proposed to address Nasdaq non-compliance.
Key Events · Earnings and Guidance · SKIN
-
Q2 Revenue Miss, EBITDA Beat
Net sales fell 7.8% YoY to $72.1M, missing the $74.3M consensus, while adjusted EBITDA of $17.0M exceeded the $11.6M estimate. Gross margin improved to 68.4% from 62.8% a year ago.
-
$18M Securities Settlement Recorded
The company accrued an $18M liability for the securities class action settlement, with $15M covered by insurance and $3M from its own funds. A corresponding $15M insurance receivable was also recorded.
-
Nasdaq Delisting Risk and Reverse Split Proposal
SkinHealth received a Nasdaq delisting notice for a sub-$1.00 bid price and has proposed a reverse stock split (1-for-5 to 1-for-20) to regain compliance. The stock closed at $0.693 on August 6, 2026.
-
Cash Position and Debt Repayment Plans
Cash and equivalents stood at $206.1M at quarter-end. The company intends to repay the remaining $103.2M of 2026 convertible notes at maturity in Q3 2026 using cash on hand.
Analysis · SKIN · Industrial Applications And Services
A 7.8% drop in revenue to $72.1M—missing consensus—reflects an 18.4% decline in Delivery System sales amid soft macro conditions. Yet adjusted EBITDA of $17M handily topped the $11.6M estimate, thanks to cost cuts and a gross margin surge to 68.4%. The quarter also saw an $18M securities class action settlement recorded, of which only $3M comes from company cash. With $206M in cash and a reverse stock split proposed to cure a Nasdaq delisting notice, the results underscore both operational resilience and lingering legal and listing overhangs.
At the time of this filing, SKIN was trading at $0.69 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $99.9M. The 52-week trading range was $0.55 to $2.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.